IGC
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic creams to treat pain under the Holief brand name; CBD powered beauty and skincare products under the Herbo brand name; and CBD infused beverages under the Sunday Seltzer brand. The company also engages in the wholesale of hemp extract under the Holi Hemp brand; production of products, such as lotions, creams, and oils, as well as white labeling support services; and extraction and distillation of crude oil into hemp extracts. It operates in the United States, India, Colombia, and Hong Kong. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma, Inc. (IGC) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (C-). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B- (2.9) | C- (1.9) | B (3.2) | C (2.2) | C+ (2.6) | C+ (2.6) |
| 2026-11-05 | B- (2.9) | C- (1.9) | B (3.2) | C (2.4) | C+ (2.7) | C+ (2.6) |
| 2026-10-29 | B- (2.9) | C- (1.9) | B (3.2) | C (2.4) | C+ (2.7) | C+ (2.6) |
| 2026-10-22 | B- (2.9) | C- (1.9) | B (3.2) | C- (2.1) | C+ (2.6) | C+ (2.5) |
| 2026-10-15 | B- (2.9) | C- (1.9) | B (3.2) | C (2.4) | C+ (2.6) | C+ (2.6) |